Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Change in Accured Expenses (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Change in Accured Expenses data on record, last reported at $102000.0 in Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 537.5% year-over-year to $102000.0; the TTM value through Sep 2025 reached $17.1 million, up 27.42%, while the annual FY2024 figure was $22.1 million, 720.15% up from the prior year.
  • Change in Accured Expenses reached $102000.0 in Q3 2025 per ZBIO's latest filing, down from $16.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $16.3 million in Q2 2025 and bottomed at -$11.2 million in Q1 2025.
  • Average Change in Accured Expenses over 3 years is $3.8 million, with a median of $1.8 million recorded in 2023.
  • The widest YoY moves for Change in Accured Expenses: up 537.5% in 2025, down 3432.84% in 2025.
  • A 3-year view of Change in Accured Expenses shows it stood at $3.2 million in 2023, then skyrocketed by 267.0% to $11.9 million in 2024, then tumbled by 99.14% to $102000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $102000.0 in Q3 2025, $16.3 million in Q2 2025, and -$11.2 million in Q1 2025.